Two Stocks Under Discussion: Match Group, Inc. (NASDAQ:MTCH), TG Therapeutics, Inc. (NASDAQ:TGTX)

Match Group, Inc. (NASDAQ:MTCH)

Match Group, Inc. (NASDAQ:MTCH) closed at $88.93 on the last trading session with an increase of 3.44%, whereas, it previously closed at $85.97. The company has a market capitalization of $24.99 Billion. The company traded shares of 3.03 Million on the trading day while its three month average volume stands at 2.61 Million.

Now to discuss some of the Earning per Share estimates and growth estimates, shares of Match Group, Inc. (NASDAQ:MTCH) produced diluted EPS of 1.96. The EPS estimate for next year as estimated by analysts is at 2.31 while EPS for next quarter is estimated at 0.42. Earnings per Share growth for this year is reported at 13, while the analysts estimated the EPS growth for next year at 2.31% and Earnings growth for next 5 years stands at 15% as estimated by the analysts. While Annual EPS Growth rate for past five years as reported by the company is at 24.4%.

Some important ratios are also vital to discuss the performance of the company and its shares. The P/E or Price to Earnings ratio of Match Group, Inc. (NASDAQ:MTCH) is at 45.3 while the forward p/e is at 38.56. The P/S or Price to Sales ratio of Match Group, Inc. (NASDAQ:MTCH) stands at 11.73 and Price to Book or P/B for the most recent quarter stands at 84.7. The Price to Free Cash Flow ratio or P/FCF is reported at 41.52. The quick ratio and the current ratio of Match Group, Inc. (NASDAQ:MTCH) are reported at 2.7 and 2.7 respectively. The Return on Assets ROA, Return On Earnings ROE and ROI Return On Investment for Match Group, Inc. (NASDAQ:MTCH) stands at 23.1, 217.4 and 32.8 respectively

The trailing twelve month Revenue of Match Group, Inc. (NASDAQ:MTCH) is reported at 2.13 Billion with income of 571.5 Million. The outstanding shares of Match Group, Inc. (NASDAQ:MTCH) are 282.83 Million. The institutional Ownership of the shares of 0 stands at 0.80%, this figure is increased 4.1 in the last six months. The insider ownership for the shares of Match Group, Inc. (NASDAQ:MTCH) is ticked at 25.8%, the figure is plummeted -0.35% in the last six months.

Some other important financial aspects to be discussed here for Match Group, Inc. (NASDAQ:MTCH) is the Mean Target Price estimated by the analysts which stands at 83.41. The 52 week high of Match Group, Inc. (NASDAQ:MTCH) is placed at 95.32 and 52 week low is standing at 44.74.

Performance wise the shares of Match Group, Inc. (NASDAQ:MTCH) rose up 5.07% for the week, it also rise 18.2% for the monthly performance, while for the quarter it went down 37.24%. The shares increase 28.36% for the half year and flew up for the Year-To-Date performance. The shares of Match Group, Inc. (NASDAQ:MTCH) grew 28.29% for the yearly performance.

TG Therapeutics, Inc. (NASDAQ:TGTX)

TG Therapeutics, Inc. (NASDAQ:TGTX) closed at $19.74 on the last trading session with an decrease of -3.85%, whereas, it previously closed at $20.53. The company has a market capitalization of $2.25 Billion. The company traded shares of 1.47 Million on the trading day while its three month average volume stands at 2.42 Million.

Now to discuss some of the Earning per Share estimates and growth estimates, shares of TG Therapeutics, Inc. (NASDAQ:TGTX) produced diluted EPS of -2.01. The EPS estimate for next year as estimated by analysts is at -1.13 while EPS for next quarter is estimated at -0.34. Earnings per Share growth for this year is reported at 14.9, while the analysts estimated the EPS growth for next year at -1.13% and Earnings growth for next 5 years stands at 0% as estimated by the analysts. While Annual EPS Growth rate for past five years as reported by the company is at -3.6%.

Some important ratios are also vital to discuss the performance of the company and its shares. The P/E or Price to Earnings ratio of TG Therapeutics, Inc. (NASDAQ:TGTX) is at 0 while the forward p/e is at 0. The P/S or Price to Sales ratio of TG Therapeutics, Inc. (NASDAQ:TGTX) stands at 11256.73 and Price to Book or P/B for the most recent quarter stands at 0. The Price to Free Cash Flow ratio or P/FCF is reported at 0. The quick ratio and the current ratio of TG Therapeutics, Inc. (NASDAQ:TGTX) are reported at 1.4 and 1.4 respectively. The Return on Assets ROA, Return On Earnings ROE and ROI Return On Investment for TG Therapeutics, Inc. (NASDAQ:TGTX) stands at -162.5, 0 and -249.3 respectively

The trailing twelve month Revenue of TG Therapeutics, Inc. (NASDAQ:TGTX) is reported at 200000 with income of -188800000. The outstanding shares of TG Therapeutics, Inc. (NASDAQ:TGTX) are 105.46 Million. The institutional Ownership of the shares of 59 stands at 0.80%, this figure is increased 11.41 in the last six months. The insider ownership for the shares of TG Therapeutics, Inc. (NASDAQ:TGTX) is ticked at 9.91%, the figure is rose 0% in the last six months.

Some other important financial aspects to be discussed here for TG Therapeutics, Inc. (NASDAQ:TGTX) is the Mean Target Price estimated by the analysts which stands at 21.5. The 52 week high of TG Therapeutics, Inc. (NASDAQ:TGTX) is placed at 22.28 and 52 week low is standing at 4.95.

Performance wise the shares of TG Therapeutics, Inc. (NASDAQ:TGTX) fell down -5.23% for the week, it also rise 64.64% for the monthly performance, while for the quarter it went down 59.19%. The shares increase 163.2% for the half year and flew up for the Year-To-Date performance. The shares of TG Therapeutics, Inc. (NASDAQ:TGTX) grew 186.09% for the yearly performance.